Quick Answer
Arcadia Biosciences, Inc. reported Cash and Equivalents of $259.0 thousand for fiscal year 2025.
Arcadia Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $259.0K | -93.9% |
| 2024 | $4.24M | -34.9% |
| 2023 | $6.52M | -68.4% |
| 2022 | $20.64M | -28.0% |
| 2021 | $28.68M | +104.3% |
| 2020 | $14.04M | +66.8% |
| 2019 | $8.42M | -29.8% |
| 2018 | $12.00M | +31.5% |
| 2017 | $9.12M | +353.3% |
| 2016 | $2.01M | -91.6% |
| 2015 | $23.97M | +44.7% |
| 2014 | $16.57M | +484.5% |
| 2013 | $2.83M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.12M | -71.5% | -18.6% |
| June 30, 2025 | $1.38M | -75.0% | -56.4% |
| March 31, 2025 | $3.16M | -4.8% | -25.5% |
| December 31, 2024 | $4.24M | -34.9% | +7.8% |
| September 30, 2024 | $3.94M | -62.9% | -28.5% |
| June 30, 2024 | $5.50M | -59.2% | +65.9% |
| March 31, 2024 | $3.32M | -85.6% | -49.1% |
| December 31, 2023 | $6.52M | -68.4% | -38.6% |
- Arcadia Biosciences, Inc. showed a decrease of -93.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, Arcadia Biosciences, Inc.’s cash and equivalents has declined by 90.9% (from $2.83 million to $259.0 thousand).
- The most recent figure is from Arcadia Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: